A combined analysis of European cancer incidence, mortality, and survival reveals encouraging trends. However, variations between countries in healthcare access and treatment policies reflect in different cancer rates.
A study found that radiation treatment after radical prostatectomy was associated with a significant increase in prostate cancer-specific and overall survival. Men with rapid PSA doubling time or high Gleason score benefited from early salvage radiotherapy, which improved survival by over 75%.
A randomized phase II study found a trend towards increased survival in patients with advanced pancreatic cancer treated with axitinib plus gemcitabine compared to gemcitabine alone. The median overall survival was longer in the axitinib group, but the finding requires further investigation in a phase III trial.
A USC study found that pre-menopausal women with metastatic colorectal cancer lived longer than younger men, while older women had significantly worse overall survival. The study also showed ethnic differences in survival rates, with Hispanics and Asians having better outcomes than Caucasians and African-Americans.
A new study suggests that the depth of cancer penetration in the bowel wall affects survival rates, and proposes changes to current guidelines. Patients with thin lesions confined to the bowel wall have better survival outcomes than those with thicker cancers.
Mayo Clinic researchers found that baseline quality of life is a strong predictor of survival in cancer patients, with scores above 83 associated with increased survival time. The study suggests that identifying quality of life deficits can help physicians intervene and improve patient outcomes, potentially extending their length of life.
A randomized controlled trial found that chemotherapy with cisplatin before concurrent chemoradiation did not improve disease-free survival for patients with anal canal cancer. The therapy resulted in a higher rate of colostomy procedures and was associated with severe hematologic toxicity.
Combining stents and photodynamic therapy significantly improves survival rates for patients with advanced liver bile duct cancer, increasing it from 7 months to over 16 months. The treatment's effectiveness is attributed to the number of stent-replacement procedures and PDT sessions.
A USC study found that specific gene variants linked to colon cancer result in opposite survival outcomes for men and women. Women with certain variants had higher overall survival rates, while men with the same variants had lower survival rates.
A recent study suggests that depression care management can improve survival rates in older cancer patients. The research found that comorbid depression shortens survival time with cancer, but intervention with medication and psychotherapy can extend life among cancer patients.
A randomized controlled trial found that combining TACE and RFA therapies resulted in longer survival times for patients with large liver cancer tumors. The therapy improved survival by slowing tumor progression and blocking the blood supply to the tumor.
Researchers at St. Jude Children's Research Hospital are investigating two areas of molecular science that hold promise for improving the survival and quality of life of ALL patients, including adolescents and adults. Gene-expression profiling and pharmacogenetics may help identify targets for future therapy and reduce toxicity.
A randomized clinical trial found that postoperative chemotherapy does not improve survival in patients with localized gastric cancer. Despite promising results in advanced gastric cancer, the combination of cisplatin, epirubicin, and other chemotherapies did not show significant benefits.
Researchers found that combining stenting with photodynamic therapy improved survival rates for patients with advanced liver bile duct cancer, reducing mortality by 57% compared to stenting treatment alone. The study suggests that this combined approach can help extend survival rates for these patients.
The study analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program and found that non-Hodgkin lymphoma patients showed significant improvements in five- and 10-year survival rates, with increases ranging from 26.8 to 27.1 percentage points across all age groups and tumor subtypes.
Researchers found advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations experience longer progression-free and overall survival rates compared to those without BRCA mutations. Additionally, a majority of women with ovarian cancer are unaware that BRCA testing is available, despite it potentially improving thei...
A study found that adding gemcitabine to chemoradiation improved survival rates for pancreatic cancer patients who had surgery, but the benefit was not statistically significant. The treatment reduced local relapse and systemic metastasis in patients.
Bilateral lung transplantation in younger patients with end-stage COPD provides longer survival than single lung transplantation, with median survival times of 6.41 and 4.59 years, respectively. This finding holds true even after adjusting for pre-transplant characteristics.
Patients with HER2-positive tumours who receive trastuzumab treatment after diagnosing brain metastases have improved survival rates. The study found a correlation between triple receptor status and the incidence of brain metastases, as well as survival time.
Patients experiencing in-hospital cardiac arrests at night or on weekends have a significantly lower chance of survival than those who arrest during weekday evenings. This is due to decreased detection and treatment effectiveness, potentially resulting from patient, staff, and hospital factors.
Level I trauma centers have different survival rates for patients with similar injuries, with some centers achieving as high as 99% survival rate and others only 35%. This disparity may be due to variations in resources and processes.
A new UCLA Medical Center study shows that select patients age 65 and older can safely undergo lung transplantation with acceptable outcomes. The study found similar survival rates between younger and older patients, suggesting that age should not preclude patients from the procedure.
A 20-year study has shown a significant increase in survival rates for extremely premature infants at a top London hospital. The study found that the overall rates of survival for infants born between 22 and 25 weeks of gestation increased from 32 per cent to 71 per cent.
A study published in Clinical Cancer Research found that patients with poor disease-free survival had lower levels of specific microRNAs compared to those with better survival rates. The researchers hope that restoring these microRNAs could lead to improved treatment options for liver cancer patients.
Men with localized prostate cancer who received male hormone suppression therapy and radiation treatment had longer survival rates. However, those with moderate to high levels of comorbid illnesses did not experience this effect. Combination therapy improved overall survival in men without severe comorbidity.
A new Mayo Clinic study found that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival. In contrast, partial nephrectomy resulted in a 10-year overall survival rate of 93%. The study's findings highlight the importance of considering long-term health consequences for patients...
Researchers have developed a new method for presenting clinical trial survival data that includes all participants, overcoming the limitations of traditional Kaplan-Meier plots. This new approach provides a more accurate representation of treatment effects, enabling physicians and patients to better understand clinical trial results.
A randomized clinical trial found that adding docetaxel to anthracycline-based chemotherapy improved disease-free survival in breast cancer patients. The study showed a 4% increase in five-year disease-free survival rates, with patients receiving sequential docetaxel after doxorubicin having the best outcomes.
Research published in the Journal of Clinical Oncology found that Ashkenazi Jewish women with BRCA1 or BRCA2 gene mutations have a significantly longer survival rate compared to those without these mutations. After up to nine years of follow-up, carriers were 28% less likely to die from ovarian cancer.
A study by Indiana University researchers found that receiving primary care during cancer treatment improves cancer survival rates, especially in lung cancer patients. Primary care utilization increased median survival rates by over fourfold, highlighting the importance of comprehensive care for whole-person health.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
A Phase III clinical trial shows that patients with relapsed CLL who achieve complete response with oblimersen combination therapy live significantly longer than those treated with chemotherapy alone. The median survival time for oblimersen-treated patients is estimated to exceed 49 months, whereas it was 35 months for those on F/C alone.
A clinical trial by Mayo Clinic found a lower dose of steroids to be as effective as the standard high-dose treatment in improving overall survival rates for multiple myeloma patients. The new regimen, lenalidomide plus low-dose dexamethasone, showed significantly better results with less toxicity.
Two studies led by Johns Hopkins Bloomberg School of Public Health researchers suggest that HIV subtype E is more virulent than other subtypes, leading to significantly shorter survival rates in Thailand. The studies found a median survival time from infection to death of 7.8 years for Thai men, compared to 11 years globally.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
Researchers found that the Wwox protein keeps ErbB-4 on the cell surface, associated with better survival in breast-cancer patients. The absence of Wwox is linked to shorter survival, particularly in triple-negative breast cancers.
A study found that hospitals with higher lymph node examination rates did not see better patient survival after colon cancer surgery. The rate of detecting node-positive tumors remained the same across all hospital groups.
Researchers at Johns Hopkins Medicine found that heart transplant recipients who receive commonly used blood-vessel-opening drugs can achieve similar survival rates as those without high pressure. The study of 10,331 patients showed a reduced survival rate for those who did not respond to therapy. These findings bring new hope to hundr...
Researchers developed a new modified comorbidity index to predict post-liver-transplant survival, considering comorbidities such as coronary disease, diabetes, and COPD. This index predicted survival as well or better than other models using recipient characteristics.
A 24-week course of interferon-alpha therapy after curative treatment for HCV-associated HCC significantly reduces tumor recurrence rates and improves patient survival compared to those without interferon therapy. Patients who achieved a sustained virological response also exhibit improved liver function and prolonged overall survival.
Researchers found that children of parents who died from these cancers have significantly worse survival rates than those with good parental survival. The risk of death was increased by 75% for breast cancer and 107% for prostate cancer.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a novel mechanism to predict survival in older women with early-stage lung cancer. Higher levels of aromatase, an enzyme that produces estrogen, are associated with more aggressive disease and lower survival rates in women over 65.
Two studies found a significant increase in five- and ten-year survival rates for MM patients over the past decade, with younger patients showing the most dramatic improvement. Novel therapies have been credited with this trend, particularly among younger patients.
A prospective study found that quality of life surpasses classic predictors like disease stage and tumor size in determining survival. Patients with better quality of life scores had a significantly higher rate of survival.
A large-scale study published in CANCER journal found that a patient's emotional state has no direct or indirect effect on cancer survival or disease progression. The research analyzed data from over 1,000 patients with head and neck cancer, concluding that psychological factors are not independently prognostic in cancer management.
A study by University of Pennsylvania researchers found that emotional well-being has no influence on cancer survival, contrary to long-held beliefs. The study examined 1,093 patients with head and neck cancers and found no correlation between emotional status and overall survival.
A retrospective cohort study found that elderly patients who started dialysis between 1990 and 1999 experienced significant improvements in survival rates. Patients aged 65-74 years at the start of dialysis showed a 23% improvement in survival, while those aged 75 or more saw a 15% gain.
Researchers examined the effectiveness of intra-arterial combination chemotherapy in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The treatment led to a median survival time of 457.2 days and a one-year survival rate of 70%.
A study of 447 patients with multiple myeloma found that thalidomide improved overall survival and response rates compared to standard chemotherapy. The MPT regimen was associated with significantly better outcomes, making it a potential new treatment option for elderly patients.
A study of over 400 patients found that those over 60 years old had similar 1-year and 5-year survival rates as younger patients, with fewer rejection episodes. The researchers attribute this to the older patients' softer immune systems, which may also increase their risk of infection and cancer.
Pertuzumab prolongs survival time for women with Stage 3 ovarian cancer, a Phase II clinical trial found. The experimental drug added weeks to the standard survival period and was well-tolerated by the body.
The Phase II EPOC study found that ZD4054, an endothelin A receptor antagonist, showed no difference in progression-free survival but reported encouraging overall survival data. The compound may have potential to increase median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC.
New chemotherapy regimens such as irinotecan and oxaliplatin-based treatments have been shown to prolong the survival of patients with advanced colorectal cancer. The meta-analysis found that these regimens can provide an estimated absolute survival benefit of 8-4.7 months for certain patient groups.
A leading epidemiologist attacks a Swedish research report on cancer drug access, citing flawed methods, incorrect conclusions, and potential industry influence. The Karolinska report aimed to link national cancer survival rates with access to cancer drugs, but its methodology has been disputed.
Prophylactic cranial irradiation reduces the risk of symptomatic brain metastases and prolongs survival in small-cell lung cancer patients with extensive disease. The EORTC trial results show a significant increase in one-year survival, from 13.3% to 27.1%, after receiving prophylactic cranial irradiation.
A comprehensive study found that conventional prognostic factors do not adequately predict survival outcomes in Asian-American men with prostate cancer. Despite worse prognostic profiles, most Asian ethnic groups have better outcomes compared to white men.
A new study found that racial differences in breast cancer survival are most apparent in advanced stages of the disease, with African American women having poorer outcomes than white women. After adjusting for clinical factors, the disparities persisted, indicating non-clinical factors may contribute to survival differences.
A new study published in CANCER journal found that group therapy does not prolong the lives of women with metastatic breast cancer. However, women with estrogen receptor-negative tumors showed a survival benefit from group therapy.
A Stanford University School of Medicine researcher led by David Spiegel showed that support groups improved quality of life for participants with metastatic breast cancer, but didn't extend overall survival. However, a subgroup of patients with an aggressive form of breast cancer did experience a survival benefit from the therapy.
A new study published in CANCER found that newer drug therapies, particularly aromatase inhibitors, have improved the survival of women with metastatic breast cancer. Survival rates increased by approximately 30% as these drugs became more widely used between 1991 and 2001.